Radionetics Oncology
Patrick Fagan is a seasoned scientist with extensive experience in drug discovery and pharmacology, currently serving as Senior Scientist in In-Vitro Pharmacology at Radionetics Oncology since September 2024. Prior roles include Senior Scientist at Erasca, Inc., where research focused on early-stage oncology projects and structure-based drug discovery related to the RAS/MAPK pathway. Patrick also contributed to the understanding of receptor signaling in anti-tumor responses at IGNYTA, Inc. Other experience encompasses biochemistry and molecular biology roles across various prestigious organizations, including Johnson & Johnson, where support was provided for oncology T-Cell therapy, and Pfizer, focusing on small-molecule drug discovery. Patrick holds a BA in Biology from San Diego State University.
This person is not in any teams
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.